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Abstract
Aim: To investigate whether an intensive lifestyle intervention induces partial or
complete type 2 diabetes (T2D) remission.
Materials and methods: In a secondary analysis of a randomized, assessor-blinded,
single-centre trial, people with non-insulin-dependent T2D (duration <10 years), were
randomly assigned (2:1, stratified by sex, from April 2015 to August 2016) to a lifestyle
intervention group (n = 64) or a standard care group (n = 34). The primary outcome
was partial or complete T2D remission, defined as non-diabetic glycaemia with no
glucose-lowering medication at the outcome assessments at both 12 and 24 months
from baseline. All participants received standard care, with standardized, blinded,
target-driven medical therapy during the initial 12 months. The lifestyle intervention
included 5- to 6-weekly aerobic and combined aerobic and strength training sessions
(30-60 minutes) and individual dietary plans aiming for body mass index ≤25 kg/m2. No
intervention was provided during the 12-month follow-up period.
Results: Of the 98 randomized participants, 93 completed follow-up (mean [SD] age
54.6 [8.9] years; 46 women [43%], mean [SD] baseline glycated haemoglobin 49.3 [9.3]
mmol/mol). At follow-up, 23% of participants (n = 14) in the intervention and 7% (n = 2)
in the standard care group met the criteria for any T2D remission (odds ratio [OR] 4.4,
95% confidence interval [CI] 0.8-21.4]; P = 0.08). Assuming participants lost to follow-up
(n = 5) had relapsed, the OR for T2D remission was 4.4 (95% CI 1.0–19.8; P = 0.048).
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DOI: 10.1111/dom.13802
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Conclusions: The statistically nonsignificant threefold increased remission rate of
T2D in the lifestyle intervention group calls for further large-scale studies to under-
stand how to implement sustainable lifestyle interventions among people with T2D.
K E YWORD S
clinical trial, dietary intervention, exercise intervention, type 2 diabetes, weight control
1 | INTRODUCTION
Type 2 diabetes (T2D) is, in general, considered to be a progressive
chronic condition with few prospects of reversal1; however, T2D may
be reverted by Roux-en-Y gastric bypass, gastric sleeve surgery,2-5 or
through lifestyle interventions.6-9 Recent studies have shown that the
T2D remission rates using very-low-calorie diets are greater in people
with T2D of short duration,7-9 with the potential to re-establish pan-
creatic β-cell function among the patients with the shortest disease
duration.10 Studies on very-low-calorie diets, however, either did not
increase physical activity levels among the participants or did not pri-
oritize increasing physical activity.8,9
Physical activity improves glycaemic control11 and may counteract
inflammatory pathways related to pancreatic β-cell dysfunction.12-14
Thus, it may be speculated that focusing on increased levels of exer-
cise may facilitate T2D remission in parallel with a dietary interven-
tion. In the Action for Health in Diabetes (Look AHEAD) trial, exercise
was prioritized, but only a limited proportion of participants reached
the levels of exercise prescribed.15 Furthermore, only modest T2D
remission rates were seen in the Look AHEAD trial6; therefore, it may
be possible that a lifestyle intervention implementing a higher exercise
volume would increase T2D remission rates. In a previous study, we
reported that >50% of participants undergoing an intensive lifestyle
intervention with a focus on high volumes of exercise discontinued
their glucose-lowering pharmaceutical therapy, with concomitant
improvements in glycated haemoglobin (HbA1c) levels after a
12-month intervention indicating the potential for T2D remission.16
Nevertheless, the follow-up time precluded inferences about the
long-term rate of T2D remission.17 Recently, we conducted a observa-
tional assessment 12 months after the termination of the
intervention,18 allowing evaluation of T2D remission.
The aim of the present study was to test the hypothesis that an
intensive exercise-based lifestyle intervention, U-TURN, is superior in
introducing any T2D remission (partial or complete) compared to stan-
dard diabetes care 1 year after termination of the lifestyle interven-
tion in participants with short-lasting (<10 years) T2D.16
2 | METHODS
2.1 | Study design
The present extension study was designed as a pragmatic superiority
study based on follow-up assessment of the participants in a recent
single-centre clinical trial (Appendix S1),18 conducted in the Capital
Region of Denmark from 29 April 2015 to 17 August 2017 and includ-
ing 98 participants. The primary outcome was assessed after a
12-month intervention and published previously.16 The data for the
present extension study were based on the follow-up examinations
12 months after the primary outcome assessment (ie, 24 months from
the baseline assessments). Guidelines from the Helsinki Declaration
were followed and reporting in this article is aligned with CONSORT
standards. The study was approved by the Scientific Ethics Committee
at the Capital Region of Denmark. All participants provided oral and
written informed consent. The full trial protocol is provided in Appendix
S1. The study was registered at ClinicalTrials.gov (NCT02417012).
2.2 | Participants and eligibility
The original trial comprised 98 people with T2D, randomly allocated
to either the intensive lifestyle intervention U-TURN or standard care.
Detailed recruitment, pre-study procedures, randomization and alloca-
tion procedures are described in detail elsewhere.11,16 No blinding
was possible for this follow-up investigation. The original eligibility
criteria were T2D diagnosed within 10 years of entry to the study,
receiving ≤2 glucose-lowering medications and a body mass index
(BMI) of 25 to 40 kg/m2. People who were insulin-dependent, or had
one or more of the following complications: diabetic retinopathy;
macro-albuminuria (urine albumin-creatinine ratio ≥ 300 mg/g);
nephropathy (plasma creatinine ≥1.47 mg/dL); or HbA1c level > 56
mmol/mol (9%) were not considered eligible.
The full analysis set for the present study was derived from the
set of all randomized participants by minimal and justified elimination
of participants16; participants allocated to a treatment group (U-TURN
or standard care) were followed up, assessed and analysed as mem-
bers of that group, irrespective of their compliance to the treatment
allocation18 (intention-to-treat population). All participants originally
allocated to either the U-TURN or the standard care group were
invited to participate in the follow-up assessments 24 months after
the baseline assessment unless they explicitly declined further partici-
pation (n = 5); a total of 93 participants (95% of the original sample16)
were invited to participate in the follow-up procedures.
2.3 | Interventions
Following the baseline procedures and until 12-month follow-up, all
participants received standard care consisting of blinded, target-
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driven pharmaceutical therapy (glucose-, blood pressure- and lipid-
lowering) and lifestyle advice delivered by a diabetes nurse every third
month. Specific therapeutic goals and procedures are described else-
where.18 In addition, participants in the U-TURN lifestyle intervention
group received supervised resistance and aerobic exercise for 30 to
60 minutes, on 5 or 6 days per week. Participants randomized to the
U-TURN intervention were also provided with individually tailored
dietary plans (macronutrient distribution: 45%-60% carbohydrate,
15%-20% protein, and 20%-35% fat, with <7% saturated fat) with an
energy intake restriction during the initial 4 months of the interven-
tion.18 During the last 8 months of the intervention, the aim was to
achieve energy balance. No interventions were provided after the
assessments at 12-month follow-up.
2.4 | Outcomes and procedures
The primary outcome for the present extension study was the preva-
lence of participants in each group with partial or complete remission
of T2D when assessed after 24 months; this was defined according to
the American Diabetes Association consensus statement as the pres-
ence of all four of the following criteria: (a) fasting glucose
≤6.9 mmol/L, (b) HbA1c < 48 mmol/mol (6.5%), (c) no glucose-
lowering medications at the outcome assessments, and (d) meeting
these targets at both 12- and 24-month follow-up.17
Secondary outcome measures included changes from baseline to
24-month follow-up in HbA1c, 2-hour glucose concentration after an
oral glucose tolerance test, fasting glucose, fasting insulin, maximal oxy-
gen uptake, weight, BMI, fat mass (total and abdominal), lean body
mass, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides,
systolic and diastolic blood pressure, energy intake and self-reported
physical activity energy expenditure. Between-group differences at
24-month follow-up in the proportion of participants who obtained 5%
or 10% weight loss, and complete T2D remission (analogous to partial
remission but with fasting glucose <5.6 mmol/L and HbA1c
<39 mmol/mol) were assessed,17,19 as well as the proportion of partici-
pants with no need for glucose-lowering medication (HbA1c
≤48 mmol/mol and no glucose-lowering medication), no need for lipid-
lowering medication (LDL cholesterol <2.5 mmol/L and triglycerides
≤5.0 mmol/L with no lipid-lowering medication), no need for blood
pressure-lowering medication (systolic blood pressure ≤ 130 mmHg and
diastolic blood pressure ≤ 80 mmHg with no blood pressure-lowering
medication) at 24-month follow-up. Adverse events from baseline to
24-month follow-up were also reported.
Planned subgroup analyses assessing partial and complete T2D
remission, were performed according to phenotypic subgroups: sex;
age; T2D duration at entry to the trial and baseline risk factors;
impaired glucose tolerance (glucose value in 2-hour oral glucose toler-
ance test ≥11.1 mmol/L); impaired fasting glucose (fasting glucose
≥7.0 mmol/L); combination of impaired glucose tolerance and fasting
glucose; low cardiorespiratory fitness20; and low need for glucose-
lowering medication (≤1000 mg metformin only). A subgroup analysis
assessing remission was also performed per protocol from baseline to
12-month follow-up.21
All assessments were performed in one laboratory and the bio-
chemical analyses were completed at the central laboratory
(Rigshospitalet, Copenhagen, Denmark) using standard procedures as
described previously.18,21
2.5 | Statistical analysis
The analysis of the primary outcome was performed according to the
intention-to-treat principle using logistic regression analyses.18 Partici-
pants with outcome data indicating no, partial or complete T2D remis-
sion at 12-month follow-up were included in the analyses independent
of participation in the 24-month follow-up assessment. When zero-
event data were observed, a continuity correction was employed that
was inversely proportional to the relative size of the opposite
group.22,23 When the dichotomous outcome data are sparse (as would
be expected in the control group19), the asymptotic results can be
unreliable; therefore, Fisher's exact tests were used to calculate the
exact probability of the possible (2 × 2) tables allowing estimation of
the Wald-test-associated variance, which corresponds to the ratio of its
estimate (loge-odds ratio [OR]) to its standard error. By default, no
imputations were used (statistical or otherwise) for the analysis of the
primary endpoint, but robustness was assessed via sensitivity analyses
which evaluated missing data to explore the effect of departures from
the assumption made in the main analysis (missing at random). For the
primary outcome, we explored the impact of data not missing at ran-
dom by a simple imputation of “worst case” (missing = not in remission)
and “best case” (missing = “in remission”) scenario.24 Continuous out-
comes were analysed using a repeated-measures analysis of covariance
and reported the difference between least-squares means with 95%
confidence intervals (CIs). The model included treatment (two levels),
time (three to six levels), sex (two levels), and the possible interaction
between treatment (group) and time (months) as fixed effects, with the
baseline value of the relevant variable as a covariate and participant
identifier as a random effect. Model diagnostics were verified using
predicted values and residuals were investigated to assess the adequacy
of the models.
For the stratified analyses, the missing data were imputed based on
a worst-case assumption; that is, assuming that participants with miss-
ing data did not achieve partial or complete remission, a priori.24 The
statistical test of interaction was analysed by comparing whether the
net benefit of U-TURN over standard care varied with subgroup.25
Statistical analyses were performed using STATA/IC (StataCorp,
College Station, Texas), version 13.1, and the statistical significance
level (for superiority) was set at α < 0.05 (two-tailed). A statistical
analysis plan was completed prior to analysis (Appendix S2).
3 | RESULTS
Of the 98 participants enrolled in the trial, 87 (59 in the U-TURN and
28 in the standard care group) participated in the 24-month follow-up
assessments (Figure 1). As five participants attending the 12-month
follow-up had data indicating that they did not reach the criteria for
RIED-LARSEN ET AL. 3
partial or complete T2D remission, they were included in the analysis
set for the primary outcome (NU-TURN/standard care = 62/31). Retention
rates did not differ between the groups (P = 0.18). The mean (SD) age
at baseline was 54.6 (9.0) years, time since diagnosis was 5.1 (2.9) years,
and there was an even sex distribution (46.2% women; Table 1). Medi-
cation prescription and adherence are described in Table S1 and S2.
3.1 | Partial and complete T2D remission
The prevalence of participants reaching sub-diabetic levels of fasting
glucose and HbA1c without glucose-lowering medication at 12- and
24-month follow-ups is presented in Figure 2. At 24-month follow-up,
14 (23%) and two participants (7%) met the criteria for partial or com-
plete T2D remission in the U-TURN and standard care groups, respec-
tively (Figure 2). Whereas the odds of remission were more than
fourfold higher in the U-TURN compared with the standard care
group, the confidence limits for the OR for remission were wide (95%
CI 0.8–21.4; P = 0.08). Under the assumption that all participants lost
to follow-up relapsed (did not meet the criteria for remission), the OR
for T2D remission was 4.4 (95% CI 1.0–19.8; P = 0.048 [Figure 3]).
One participant reached complete T2D remission (in the U-TURN
group). Risk ratios for partial and complete T2D remission are
presented in Table S3. The number needed-to-treat for one partial or
complete T2D remission was seven participants, when assuming all
participants lost to follow-up had relapsed.
While the odds for complete or partial T2D remission were higher
in the U-TURN than the standard care group among men and partici-
pants with short T2D duration at baseline (Figure 3), no interactions
were observed in any of the stratified analyses (Figure 3).
3.2 | Glycaemic control
Levels of HbA1c increased and fasting insulin levels decreased in both
groups (Table 2 and Figure S1), with no between-group differences.
No intervention effects were observed on fasting glucose or 2-hour
glucose (Table 2 and Figure S2).
3.3 | Body composition
No differences between the U-TURN and standard care group were
observed in weight, BMI, fat mass, abdominal mass or fat-free mass from
baseline to 24-month follow-up (Table 2 and Figure S3). Only a limited
number of participants achieved 5% and 10% weight loss (Table 2).
Assessed for eligibility (n=878)
Randomized (n=98)
Excluded (N=356)
Withdrew (n=382)
Excluded (n=31)
Geographical distance (n=215)
Unknown reason (n=167)
Withdrew (n=11)
Medical examination (n=140)
Cardiovascular disease (n=3)
No diabetes (n=2)
Other health issues (n=6)
Other issues (n=20)
T2D diagnosis >10 years (n=141)
No diabetes or type 1 diabetes (n=17)
Usage of insulin (n=74)
HbA1c >75 mmol/mol (n=7) 
BMI <25 or >40 kg/m2 (n=28)
Unable to exercise (n=5)
Cardiovascular disease (n=29)
>2 types of glucose-lowering medications (n=8)
Other health issues (n=25)
Other issues (n=22)
Allocated to standard care (n=34)
- Received group 
Medicine titration 6 weeks prior to baseline measurement (n=98) 
allocation (n=34)Allocated to U-TURN (n=64)
- Received group allocation (n=64)
Lost to follow-up at 3 months (loss 
of contact or extent of the 
intervention) (n=2) 
Lost to follow up at 3 months 
(allocation or knee operation) 
(n=2)
Lost to follow-up at 9 months (loss 
of contact) (n=1)12-month follow-up
Analyzed (n=64) 
Excluded from analysis (n=0)
12-month follow-up
Analyzed (n=34)
Excluded from analysis (n=0)
Baseline measurement (n=98)
24-month follow-up
Analyzed (n=62) 
Excluded from analysis (n=2)
24-month follow-up
Analyzed (n=31)
Excluded from analysis (n=3)
Lost to 24-month follow-up
(withdrew) (n=2)
(loss of contact) (n=1) 
Lost to 24-month follow-up
(loss of contact) (n=2)
F IGURE 1 Flow of participants through the study. BMI, body mass index; HbA1c, glycated haemoglobin; T2D, type 2 diabetes
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3.4 | Other secondary outcomes
Physical fitness and physical activity energy expenditure increased
more from baseline to 24-month follow-up in the U-TURN group
compared to the standard care group (Table 2), and the prevalence of
participants not using blood pressure-lowering medication was higher
in the U-TURN group compared to the standard care group (Table 2).
No statistically significant differences in the remaining secondary out-
comes were observed (Table 2). More participants experienced mus-
culoskeletal pain in the intervention group compared to the standard
care group during the 24 months of follow-up (P = 0.04; Table S4).
TABLE 1 Baseline characteristics of study participants
U-TURN group Standard care group
Demographics
Number of participants 62 31
Age, y 53.5 (9.2) 56.7 (8.3)
Female, n (%) 29 (47) 14 (45)
T2D duration, years 4.7 (2.8) 5.6 (3.2)
Glycaemic control
HbA1c, mmol/mol 49.1 (9.1) 49.7 (9.8)
Fasting glucose, mmol/L 8.4 (2.9) 9.1 (3.1)
Median (interquartiles) fasting insulin,
pmol/L
113 (82; 162) 116 (65; 176)
2-h glucose, mmol/L (n = 61/30) 15.4 (4.0) 16.3 (4.2)
Lipids
Total cholesterol, mmol/L 4.2 (0.9) 4.0 (1.0)
Median (interquartiles) LDL cholesterol,
mmol/L
2.4 (1.9; 2.9) 2.1 (1.7; 2.5)
HDL cholesterol, mmol/L 1.2 (0.3) 1.3 (0.4)
Median (interquartiles) triglycerides,
mmol/L
1.5 (1.0; 1.9) 1.4 (0.8; 1.8)
Blood pressure
Systolic, mmHg (n = 59/23) 127 (14) 137 (8)
Diastolic, mmHg (n = 84) 79 (9) 84 (8)
Body composition
Body mass, kg 95.3 (14.1) 97.6 (15.4)
Body mass index, kg/m2 31.5 (3.9) 32.3 (4.4)
Fat mass, kg 35.4 (9.2) 35.8 (10.8)
Lean body mass, kg 57.9 (10.2) 57.9 (10.7)
Abdominal fat mass, kg 4.0 (1.2) 4.1 (1.3)
Physical fitness, physical activity and diet
VO2max, mL O2/min (n = 62/30) 2734 (719) 2668 (771)
Relative VO2max, mL O2/kg/min
(n = 62/30)
28.7 (6.6) 26.9 (6.2)
Median (interquartiles) physical activity,
MET h/d (n = 58/29)
18 (15; 25) 20 (15; 31)
Median (interquartiles) energy intake,
kcal/d (n = 60/25)
2160 (1720; 2574) 2224 (1614; 2637)
Medication usage
Glucose-lowering medication, n (%) 62 (98) 31 (100)
Lipid-lowering medication, n (%) 51 (80) 30 (88)
Blood pressure-lowering medication, n
(%)
31 (48) 19 (56)
Data are mean (SD), unless otherwise indicated.
Abbreviations: HbA1c, glycated haemoglobin; T2D, type 2 diabetes; VO2max, maximal oxygen uptake.
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3.5 | Post hoc outcomes
Participants meeting the criteria for any T2D remission increased their
physical fitness and reduced their abdominal fat mass and total fat
mass more from baseline to 24 months than participants not meeting
the criteria (Table S5). Remission was associated with a lower decline
in physical fitness from 12 to 24 months, but not with changes in self-
reported physical activity or dietary variables (Table S6).
4 | DISCUSSION
The main finding of the present study was that a 12-month lifestyle
intervention including high exercise volume and dietary counselling
may lead to partial T2D remission in participants with well-controlled
T2D of short duration. While the lifestyle intervention increased phys-
ical fitness, no differences in indices of glycaemic control, lipidaemia
or body composition, were observed between the groups 12 months
after completing the intervention.
The rate of partial or complete T2D remission, using the same
criteria as in the present study, is extremely low in a representative
general diabetes population.19 Moreover, the chance of partial T2D
remission decreases with time since diagnosis and when glucose-
lowering pharmacological treatment needs intensification.19 In a sub-
population with similar duration of T2D duration to that of the popu-
lation receiving an intensive lifestyle intervention in the present study
(4–5 years), Karter et al19 observed a considerably lower T2D remis-
sion incidence (<2% vs. 23%). However, as a result of the stringent
sampling frame, the present study population was probably more will-
ing and motivated to engage in lifestyle change as compared to the
background population, which renders direct comparison difficult. In
the Look AHEAD study, the rate of any T2D remission was 10.4%
after 2 years in the intensive lifestyle intervention group,6 which was
similar to the T2D remission incidence in the standard care group
(7%). This is not surprising given the extensiveness of the treatment
regimen in the standard care group18; however, several notable differ-
ences between the study designs limit direct comparisons. The Look
AHEAD trial included participants with longer T2D duration, greater
comorbidity burden and older age, all factors that decrease the chance
of T2D remission in lifestyle interventions.6,8,19 In addition, the remis-
sion criteria used in the Look AHEAD study did not stipulate that the
prediabetic glucose levels should be maintained without glucose-
lowering medication for a prolonged period of time (ie, ≥1 year).
Finally, contrary to the Look AHEAD intensive lifestyle group, the
1 year that followed the termination of the intensive lifestyle inter-
vention in the present study was an observational period (ie, no inter-
vention was provided). In comparison with intensive dietary treatment
without exercise intervention, the T2D remission rates (as defined by
HbA1c ≤48 mmol/mol without glucose-lowering medication) in the
U-TURN group were similar 1 year after the intervention7; Hence, at
24-month follow-up, the DIRECT trial showed partial or full T2D
remission in 36.5% of the participants in the intervention group7
which is comparable to 34% in the U-TURN group. Whereas the
DIRECT follow-up study showed a concomitant weight loss, participa-
tion in the U-TURN intervention was not associated with weight loss
but with an increase in physical fitness. As T2D remission in the pre-
sent study was associated with an increase in fitness levels from base-
line to 24-month follow-up, this may suggest that T2D remission in
the present study was obtained by exercise and not only dietary
changes. This is highly speculative, however, and the observation
needs replication.
Although no quantitative interaction could be detected in the con-
textual analyses, we observed qualitative sub-group effects in
response to the intervention among participants with shorter T2D
duration and among men but not among participants with longer T2D
duration and women. In line with previous lifestyle interventions,
short T2D duration is a predictor for T2D remission in lifestyle inter-
vention studies.6,10,26 This may relate to the underlying pathogenesis
of T2D which involves declining β-cell function.10,27 In support of this,
Dela et al26 observed that, while patients with T2D who had
remaining insulin secretory capacity improved their pancreatic β-cell
function in response to a training intervention, patients without
remaining secretory capacity did not.26 Collectively, this highlights the
importance and clinical significance of introducing intensive lifestyle
interventions as soon as possible after T2D diagnosis to potentially
revert the disease. Contrary to other lifestyle interventions,6,8 we
observed an intervention effect on T2D remission among men but not
among women; however, the significance of that observation is uncer-
tain as the men also had a shorter average T2D duration. In line with
F IGURE 2 Prevalence of participants with fasting glucose below
the diagnostic threshold for type 2 diabetes (T2D [≤6.9 mmol/L]) and
glycated haemoglobin (HbA1c) <48 mmol/mol without glucose-
lowering medication at 12 months, 24 months and at both time points
(any T2D remission). White bars indicate the standard care group and
the grey bars are the U-TURN group. Mean median values following
multiple bootstrap samples (1000 samples with replacement), with the
corresponding empirical 95% CIs (ie, 2.5 and 97.5 percentiles) are
shown. Data are as-observed with raw case/denominators for the
control group at 12 months (3/31), at 24 months (3/28) and at both
time points (2/31) and the corresponding raw case/denominators for
the U-TURN group at 12 months (23/62), at 24 months (15/59) and
at both time-points (14/62)
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other lifestyle intervention studies, the present study indicates that
partial T2D remission may be obtainable when participants are
engaged in an intensive lifestyle intervention. We extend the existing
knowledge by showing that a subgroup of participants was able to
maintain glucose levels below the diagnostic criteria without the use
of glucose-lowering medications 1 year after the termination of a life-
style intervention programme (ie, without maintenance support).
The present study has several limitations. First, some ambiguity
exists around the concept of remission. The American Diabetes
Association consensus statement defined remission as hyper-
glycaemia below the diagnostic level for diabetes (partial remission)
or returning to the normal level (complete remission) in the absence
of active glucose-lowering therapy. Importantly, these targets should
be maintained for at least 1 year.17 Moreover, a lowering of fasting
glucose or HbA1c alone or in absence of glucose-lowering medica-
tions may not appropriately reflect a decreased risk of complica-
tions.28 This is further underpinned by our observation that only
maximal oxygen uptake and not indices of glycaemic control or
body composition were improved. However, it has been suggested
that T2D remission attributable to a large diet-induced weight loss
reflects a reversion of T2D pathophysiology,10 suggesting clinical
relevance. Second, the adherence to glucose-lowering medical ther-
apy at 24-month follow-up was self-reported, thus was prone to
information bias. Consequently, the difference in T2D remission
rates may be overestimated if the bias were differential (ie, more
frequent in the U-TURN or standard care group). Third, T2D remis-
sion was not a designated outcome in the present study, rendering
the present findings exploratory,18 consequently, the study was not
powered for this analysis and may, therefore, be underpowered.
Moreover, although the primary analysis did not reach the level of
statistical significance, the worst-case scenario sensitivity analyses
did. This analysis was made under the assumption that participants
lost to follow-up did not achieve any T2D remission. This is a rea-
sonable assumption because the chance of reaching any T2D remis-
sion in the background population is very low19; therefore, the
best-case scenario (all participants lost to follow-up achieve any
T2D remission) is probably not realistic. As no apparent difference
in the point estimate between the primary analysis and the worst-
case scenario was seen, this suggests that the effect of the lifestyle
intervention on T2D remission was robust.
Overal
Worst case
Best case
Male
Young
Short T2D duration
IGT
IFG
IGT and IFG
Low CRF
High dose GLM
Per protocol
Obesity
4.2 (0.8−21.4)14/62 (23)2/31 (7)
4.4 (1.0−19.8)14/64 (22)2/34 (6)
1.9 (0.6−6.8)16/64 (25)5/34 (15)
No
Yes
1.0 (N/E)
23.4 (2.2−249.4)
10/33 (30)0/18 (0)
4/31 (15)2/16 (13)
No
Yes
3.6 (0.2−74.2)        0.85
5.3 (0.6−46.9)
8/24 (25)1/17 (6)
6/32 (19)1/17 (6)
No
Yes
1.4 (N/E)
16.8 (1.1−254.8)
4/32 (13)2/21 (11)
10/32 (31)0/13 (0)
No
Yes
5.0 (0.1−262.2)      0.86
4.7 (0.5−39.9)
5/7 (71)1/3 (33)
9/51 (21)1/23 (5)
No
Yes
4.5 (0.1−178.3)      0.91
2.8 (0.03−262.3)
9/11 (82)1/2 (50)
5/46 (12)1/24 (4)
No
Yes
6.0 (0.3−120.7)      0.78
2.8 (0.1−235.8)
3/12 (25)1/3 (33)
4/45 (13)1/23 (5)
No
Yes
14.6 (0.7−287.7)    0.35
2.4 (0.2−23.4)
7/29 (24)0/13 (0)
7/35 (20)2/21 (11)
No
Yes
3.0 (0.4−22.5)         0.51
10.5 (0.4−253.8)
9/38 (24)2/19 (12)
5/26 (20)0/13 (0)
No
Yes
5.2 (N/E)
5.6 (1.2−27.3)
3/30 (10)0/8 (0)
11/34 (33)2/26 (8)
No
Yes
12.6 (0.4−293.4)    0.44
2.7 (0.4−17.0)
6/26 (30)0/12 (0)
8/38 (27)2/22 (10)
Subgroup Interventionstandard care Odds ratio (95% CI)
No. events/no. participants (%)
*
*
*
*
*
*
0.
1
0.
5
1.
0
2.
0
5.
0
10
.0
50
.0
10
0.
0
25
0.
0
P value
for interaction
standard care group better U−TURN group better
F IGURE 3 Overall and subgroup (predefined based baseline levels) effects of an intensive lifestyle intervention vs. standard care on the
occurrence of full or partial type 2 diabetes (T2D) remission at 24-month follow-up in participants with T2D. Young is defined as age < 54 years,
based on a median split of age; short T2D duration as <5 years, based on a median split of disease duration, impaired glucose tolerance (IGT) as
2-hour glucose concentration ≥ 11.1 mmol/L during an oral glucose tolerance test, impaired fasting glucose (IFG) as fasting glucose ≥7.0 mmol/L,
low cardio-respiratory fitness (CRF) as maximal oxygen consumption <2623 mL O2/min, based on a median split of age, high-dose glucose-lowering
medication (GLM) as >1000 mg metformin, and obesity as body mass index >30 kg/m2. Per protocol indicates the presence of all the following
criteria during the intervention: U-TURN group: 1) attending at least four (of five) medical consultations, 2) completing ≥70% of all exercise sessions
and 3) only receiving the prescribed medications and/or the prescribed combination of medications according to the treatment algorithm; standard
care group: 1) attending at least four (of five) medical consultations and 2) only receiving the prescribed medications and/or the prescribed
combination of medications according to the treatment algorithm. *Analyses are based on continuity corrected data. N/E, not estimeble
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In conclusion, an intensive 12-month exercise-based lifestyle
intervention was associated with nonsignificant partial or complete
T2D remission in 23% of all participants compared with only 7% par-
ticipants receiving standard care. Nevertheless, the difference in this
relatively small sample size did not reach statistical significance and
further studies on maintaining a lifestyle change are needed.
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